| Document |
Document Title |
|
WO/2022/207648A1 |
A PI3K-delta inhibitor or a pharmaceutically acceptable salt thereof for use in a method of treatment of pancreatic cancer in a patient, optionally wherein the method further comprises administration of an autotaxin (ATX) inhibitor or a ...
|
|
WO/2022/211027A1 |
The present invention provides: a CD9 signal suppressing agent that includes the amino acid sequence of RSHRLRLH (SEQ ID NO: 1) or includes the SEQ ID NO: 1 amino acid sequence where one or more amino acids are deleted, substituted, or a...
|
|
WO/2022/207673A1 |
The Application describes a new target for the treatment of pain and identifies suitable compounds for use in the invention.
|
|
WO/2022/212894A1 |
The disclosure features methods for inhibiting RAS proteins, e.g., RAS proteins that have acquired resistance to one or more RAS inhibitors. The disclosure also methods for the treatment of cancer.
|
|
WO/2022/212571A1 |
The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising dosing a human subject with L-asparaginase.
|
|
WO/2022/206881A1 |
The present invention relates to the field of biotechnology drugs. In particular, provided in the present invention is an antibody-drug conjugate (ADC) complex based on a complementary and paired nucleic acid skeleton. The ADC complex is...
|
|
WO/2022/173711A9 |
The present disclosure provides methods for inhibiting cell proliferation, inducing differentiation, and inducing replication stress in a cancer cell. The present disclosure also provides methods for treating a cancer in a patient. Vario...
|
|
WO/2022/211060A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease associated with ABHD6, which contains a compound having an ABHD6-inhibiting activity as an active ingredient. A compound repre...
|
|
WO/2022/211829A1 |
The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising dosing a human subject with L-asparaginase.
|
|
WO/2022/210863A1 |
The purpose of the present invention is to provide, inter alia: a detection agent for specifically detecting bladder cancer stem cells; a tumor antigen peptide that is specifically presented by bladder cancer stem cells; a drug compositi...
|
|
WO/2022/212890A1 |
A method for identifying a therapy recommendation for a subject exhibiting dysregulated host response e.g., dysregulated immune response manifesting clinically as sepsis, is provided. Quantitative expression of a panel of biomarkers is a...
|
|
WO/2022/207631A1 |
The invention provides a method for providing postcoital contraception in a woman, which method comprises administering a woman, who had an unprotected intercourse typically more than 120h before, with a progestogen during 1 to 3 days, f...
|
|
WO/2022/203267A1 |
Provided are a dual antagonist for adenosine A2A receptor and adenosine A2B receptor, a pharmaceutical composition containing same for prevention or treatment of diseases (e.g., cancer) related to adenosine A2A receptor and adenosine A2B...
|
|
WO/2022/202950A1 |
The present invention pertains to: a biomarker for predicting response to IL-6 signal transmission pathway-targeting therapy in pulmonary arterial hypertension patients; and a patient selection method.
|
|
WO/2022/204084A1 |
The present invention relates to methods for inhibiting human immunodeficiency virus (HIV) from entering latency in an infected subjected by co-administering an antiretroviral therapy regimen (ART) and a histone deacetylase (HDAC) inhibi...
|
|
WO/2022/200857A1 |
The present disclosure relates to a. compound of formula I or a. pharmaceutically acceptable salt thereof Formula I wherein A is Formula II X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 m...
|
|
WO/2022/203000A1 |
The present invention addresses the problem of providing a fusion protein that is for use in treatment or diagnosis of cancer and that is formed between a streptavidin variant and a molecule that recognizes a cancer cell or the like. The...
|
|
WO/2022/204504A1 |
Compositions and methods for modified viral vectors which mitigate the immunogenicity of viral vectors, enabling multiple administrations of viral-based gene delivery viral vectors are described herein. The viral vectors advantageously p...
|
|
WO/2022/203399A1 |
The present invention relates to an antagonist of an adenosine A2A receptor, a pharmaceutical composition containing same for preventing or treating adenosine A2A receptor-related disease (for example cancer), and a method for treating a...
|
|
WO/2022/202138A1 |
The present invention discloses a composition for a sustained-release solid preparation, said composition comprising: (A) a polyvinyl alcohol-based resin having an average degree of saponification of 78-96 mol% and an average degree of p...
|
|
WO/2022/200613A2 |
The invention relates to the treatment or prevention of myeloproliferative disorders and other hematopoietic malignancies. Herein is described a carbonic Anhydrase 1 (CA1) inhibitor; for use in a method for treating or preventing a myelo...
|
|
WO/2022/204228A1 |
Pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI) and a mineralocorticoid antagonist and optionally a muscarinic receptor antagonist (MRA) and methods of treating sleep apnea are described herein.
|
|
WO/2022/200615A1 |
The present invention relates to novel treatment strategies comprising compositions, methods, uses, and kits, including a kit of parts, for the treatment and/or prevention of a viral infection in a subject, for example, a coronavirus inf...
|
|
WO/2022/201065A1 |
The present disclosure relates to the field of oncology and particularly towards a combination therapy for treatment of cancer. In particular, the present disclosure provides a combination therapy comprising chloroquine, metformin and st...
|
|
WO/2022/200478A1 |
The disclosure provides methods and compositions for treating tumors, particularly HER2- expressing tumors, including tumors characterized by a low expression of HER2 and HER2- positive (HER2+) tumors. The method comprises administering ...
|
|
WO/2022/199237A1 |
Provided are modified amino acids and an application thereof in ADC. The modified amino acids are phosphorylcholine group-modified amino acids represented by R1-L1-N(R2)-R3, wherein R1, L1, N, R2 and R3 are as defined herein. Further pro...
|
|
WO/2022/198742A1 |
A superparamagnetic modified neutrophil exosome bionic vesicle drug delivery biological preparation and a preparation method therefor, characterized in that, the preparation method comprises the following steps: 1) co-culturing periphera...
|
|
WO/2022/200848A1 |
The present invention relates to pterostilbene for use in the treatment or prevention of infertility in an individual who is affected by infertility or a decline in fertility or who is at risk of suffering from infertility or a decline i...
|
|
WO/2022/204517A1 |
This disclosure relates to formulations containing arginine and other ingredients useful in managing acute and chronic complications of coronavirus infections, including respiratory symptoms fatigue, hypercoagulable state, cardiac sympto...
|
|
WO/2022/203070A1 |
The present invention addresses the problem of providing a pharmaceutical composition that improves cardiac function when administered during a coronary artery bypass surgery for ischemic cardiomyopathy. A pharmaceutical composition for ...
|
|
WO/2022/200473A1 |
The present invention relates to PPARγ agonists or MPC inhibitors, in particular from the group of thiazolidine-2,4-diones, and to a pharmaceutical composition containing such agonists for use in a method for the prevention or therapy o...
|
|
WO/2022/201832A1 |
The present invention addresses the problem of providing a novel GLP-1 secretion promotion agent. The present invention provides a GLP-1 secretion promotion agent that includes a GPR84 agonist as an active ingredient.
|
|
WO/2022/204526A1 |
Described herein are compositions and methods for treating inflammatory arthritic conditions that are effective systemically without causing generalized immunosuppression when administered locally into an inflammatory arthritis-affected ...
|
|
WO/2022/202947A1 |
Disclosed is a stable aqueous pharmaceutical composition or freeze-dried pharmaceutical composition that comprises a protein as an active ingredient. This pharmaceutical composition comprises a protein having a physiological activity and...
|
|
WO/2022/204386A2 |
Small molecule inhibitors that block the interaction between B-cell lymphoma 10 protein (BCL10) and mucosa- associated lymphoid tissue lymphoma translocation protein 1 (MALT1), thereby inhibiting both the protease and scaffolding activit...
|
|
WO/2022/200575A1 |
The present invention relates to carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.
|
|
WO/2022/202099A1 |
[Problem] Problems addressed are: to provide a new test method for inflammatory bowel disease; to provide a method for screening substances or microorganisms for prevention or treatment of inflammatory bowel disease; and to provide a com...
|
|
WO/2022/200339A1 |
A compound of formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, for use in the treatment of hidradenitis suppurativa (HS) in a subject.
|
|
WO/2022/200334A1 |
The present invention relates to a nutraceutical composition comprising inulin and a Chilean wineberry extract, and also other ingredients such as amino acids, vitamins and/or trace elements, in particular for the use thereof in preventi...
|
|
WO/2022/204376A1 |
Provided herein are methods for treating NTM lung disease in a patient in need thereof. The methods comprise administering to the patient for an administration period (i) a liposomal amikacin composition and (ii) a second active agent th...
|
|
WO/2022/204137A1 |
Methods, systems and devices are disclosed that provide, among other benefits, an adequate and effective pain management that can be implemented as part of surgical planning, pain management, and other applications. An example methodolog...
|
|
WO/2022/200557A1 |
Combination Treatments for Melanoma This specification discloses the use of an ATR inhibitor in combination with an immune checkpoint inhibitor for the treatment of melanoma in a patient who has previously received immunotherapy.
|
|
WO/2022/204562A1 |
The disclosure is in part directed to shelf-stable, emulsion-forming liquid compositions, liquid beverage compositions, and fatty acid vesicle-forming liquid compositions for increased neurosystem uptake of amino acids present in the com...
|
|
WO/2022/203718A1 |
A method of inducing a Type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed ...
|
|
WO/2022/200574A1 |
The present invention relates to a carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.
|
|
WO/2022/200982A1 |
This invention relates to combination therapies comprising talazoparib, or a pharmaceutically acceptable salt thereof, and an anti-androgen, or a pharmaceutically acceptable salt thereof, and associated pharmaceutical compositions, metho...
|
|
WO/2022/204606A1 |
This disclosure relates generally to compositions and methods for treating cancer. This disclosure relates more particularly to compositions and methods suitable for treating cancer that are associated with a high level of neutrophil ext...
|
|
WO/2022/195521A1 |
The invention provides an oromucosal film composition comprising: a therapeutically effective amount of epinephrine solid particles having a particle size in the range of from about 0.01 um to about 100 um; and a pharmaceutically accepta...
|
|
WO/2022/198092A1 |
In some aspects, the present disclosure provides pharmaceutical compositions comprising particles, wherein individual particles of the composition comprise a combination of two or more active pharmaceutical ingredients selected from: (A)...
|
|
WO/2022/194905A1 |
The present invention relates to the compounds (I) wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
